Oasmia Pharmaceutical (OASMY) Stock Price, News & Analysis

Company Overview

Oasmia Pharmaceutical AB is a Sweden‐based biotechnology company focused on the development and commercialization of innovative therapeutic products in both human and veterinary medicine. The company’s core expertise lies in formulation and delivery technologies designed to improve the efficacy and safety profiles of established oncology drugs. Leveraging its proprietary XR–17 micellar drug delivery platform, Oasmia aims to enhance solubility and bioavailability of active pharmaceutical ingredients, with a particular emphasis on taxane‐based chemotherapeutic agents.

Oasmia’s lead human oncology product, Apealea (paclitaxel micellar), has received regulatory approval in the European Union and the United Kingdom for the treatment of ovarian cancer. In the veterinary segment, the company markets Paccal Vet, a paclitaxel formulation for canine mammary carcinoma and mast cell tumors, as well as Doxophos Vet for canine lymphoma. These products are approved in multiple territories, including the United States, Europe and Russia, underscoring Oasmia’s commitment to addressing oncological needs across diverse patient populations.

Since its founding, Oasmia has pursued a dual human‐veterinary strategy that provides cross‐sector synergies in research, development and regulatory affairs. Headquartered in Uppsala, Sweden, the company operates research facilities and maintains partnerships with academic institutions and contract development organizations worldwide. Oasmia is governed by an experienced board of directors and executive management team with backgrounds in pharmaceutical development, regulatory affairs and global commercialization.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.02
• 52-Week Range: $0.01 to $0.05
• Volume: N/A
• Average Volume: 5 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OASMY Stock Analysis - Frequently Asked Questions

How have OASMY shares performed this year?

Oasmia Pharmaceutical's stock was trading at $0.04 at the beginning of 2025. Since then, OASMY shares have decreased by 50.0% and is now trading at $0.02.

How do I buy shares of Oasmia Pharmaceutical?

Shares of OASMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/09/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OASMY
• CIK: 1607245
• Web: www.oasmia.com
• Phone: (461) 850-5440
• Fax: 461-851-0873
• Employees: 20
• Year Founded: 1990

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $100 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 28.87